Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin
Status:
Withdrawn
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
Two arm, randomized, open-label study, to determine the best time to secondary resistance
between responding patients who discontinue treatment and resumed Trabectedin at the time of
progression versus patients who continued treatment until progression. T